{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:44:12Z","timestamp":1761093852346,"version":"build-2065373602"},"reference-count":16,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3548,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2002,5]]},"abstract":"<jats:p>Blood dyscrasias, although rare, can be fatal. Many drugs, including antibiotics, are associated with these dyscrasias. We conducted a cohort study with a nested case\u2010control analysis using data from the General Practice Research Database to estimate incidence rates of clinical blood dyscrasias in the general population and to examine their association with use of antibiotic drugs. The study population consisted of patients aged 5\u201369 years receiving at least one antibiotic prescription from January 1994\u2010September 1998. The final cohort consisted of 822,048 persons who received 1,507,307 antibiotic prescriptions during the study period. The main outcome measure was a diagnosis of neutropenia, agranulocytosis, hemolytic anemia, thrombocytopenia, bicytopenia, pancytopenia, or aplastic anemia. We confirmed 122 patients who developed clinical blood dyscrasias. The incidence was 3.3\/100,000 person\u2010years in the general population. Patients older than 60 years (relative risk [RR] 2.8, 95% confidence interval [CI] 1.6\u20135.0) and those who took phenothiazines (RR 49.0, 95% CI 4.9\u2013488.2) had an increased risk of blood dyscrasia. Users of antibiotics had an RR of 4.4 (95% CI 2.6\u20137.5), and patients taking more than one class of antibiotics had an RR of 29.1 (95% CI 9.1\u201392.8). Among individual antibiotic classes, the greatest risk was with cephalosporins (RR 13.8, 95% CI 3.6\u201352.6). Although uncommon, our study supports an association between blood dyscrasias and antibiotics.<\/jats:p>","DOI":"10.1592\/phco.22.8.630.33203","type":"journal-article","created":{"date-parts":[[2004,5,21]],"date-time":"2004-05-21T11:37:53Z","timestamp":1085139473000},"page":"630-636","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Risk of Clinical Blood Dyscrasia in a Cohort of Antibiotic Users"],"prefix":"10.1002","volume":"22","author":[{"given":"Consuelo","family":"Huerta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Alberto Garc\u00eda","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"volume-title":"The drug etiology of agranulocytosis and aplastic anemia","year":"1991","author":"Kaufman D.W.","key":"e_1_2_1_2_2"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/archinte.1992.00400190095018","article-title":"Descriptive epidemiology of agranulocytosis","volume":"152","author":"Strom B.L.","year":"1992","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00072-9"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.V75.8.1646.1646","article-title":"Epidemiology of aplastic anemia in France: a prospective multicentric study","volume":"75","author":"Mary J.Y.","year":"1990","journal-title":"Blood"},{"key":"e_1_2_1_6_2","first-page":"426","article-title":"Incidence of aplastic anaemia in a three county area in South Carolina","volume":"46","author":"Linet M.S.","year":"1986","journal-title":"Cancer Res"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199411060-00006"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-11_Part_1-199812010-00009"},{"issue":"2","key":"e_1_2_1_9_2","first-page":"115","article-title":"Drug\u2010induced hemolytic anemias: increasing complications to therapeutic intervention","volume":"12","author":"Wright M.S.","year":"1999","journal-title":"Clin Lab Sci"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1982.tb03216.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/152.1.90"},{"issue":"6","key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1182\/blood.V81.6.1471.1471","article-title":"Epidemiology of aplastic anemia in France: a case\u2010control study. I. Medical history and medication use. The French cooperative group for epidemiological study of aplastic anaemia","volume":"81","author":"Baumelou E.","year":"1993","journal-title":"Blood"},{"issue":"5","key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/archinte.1989.00390050040008","article-title":"Anti\u2010infective drug use in relation to the risk of agranulocytosis and aplastic anemia","volume":"149","author":"International Agranulocytosis and Aplastic Anemia Study Group.","year":"1989","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2125.1998.00701.x","article-title":"Use of the UK General Practice Research Database for pharmacoepidemiology","volume":"45","author":"Rodr\u00edguez L.A. Garc\u00eda","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.302.6779.766"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2630010406"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03148.x"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.22.8.630.33203","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.22.8.630.33203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:00:26Z","timestamp":1761051626000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.22.8.630.33203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["10.1592\/phco.22.8.630.33203"],"URL":"https:\/\/doi.org\/10.1592\/phco.22.8.630.33203","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2002,5]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}